Implantable cardioverter and defibrillator therapy

Ahsanuddin Ahmad, Ania Garlitski, Mark Link, Munther K. Homoud, N. A.Mark Estes

Research output: Chapter in Book/Report/Conference proceedingChapter


Internal cardioverter defibrillator (ICD) therapy is extremely effective in terminating ventricular tachycardia or ventricular fibrillation (VT/VF) and reducing total mortality in select populations. Common indications for ICDs include survival of prior cardiac arrest, unexplained syncope with inducible VT/VF on electrophysiology study, ischemic cardiomyopathy with EF ≤30 % in patients who are more than 40 days post-myocardial infarction, and cardiomyopathy (ischemic or nonischemic) with EF ≤35 % and New York Heart Association (NYHA) Class II-III heart failure symptoms. ICDs may also be indicated in certain individuals from special populations who suffer from inherited conditions which predispose to sudden cardiac death such as hypertrophic cardiomyopathy, long QT syndrome, Brugada syndrome, arrhythmogenic right ventricular dysplasia, catecholaminergic polymorphic ventricular tachycardia, and cardiac sarcoidosis.

Original languageEnglish (US)
Title of host publicationEvidence-Based Cardiology Consult
PublisherSpringer-Verlag London Ltd
Number of pages13
ISBN (Electronic)9781447144410
ISBN (Print)1447144406, 9781447144403
StatePublished - Nov 1 2014


  • Arrhythmogenic right ventricular dysplasia
  • Brugada syndrome
  • Cardiac resynchronization therapy (CRT)
  • Cardiac sarcoidosis
  • Catecholaminergic polymorphic ventricular tachycardia
  • Internal cardioverter defibrillator (ICD) indications
  • Internal cardioverter defibrillator (ICD) therapy
  • Ventricular fibrillation
  • Ventricular tachycardia

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Implantable cardioverter and defibrillator therapy'. Together they form a unique fingerprint.

Cite this